Aktis Oncology, Inc.
AKTS
$20.34
$1.226.38%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 123.01% | 100.43% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 123.01% | 100.43% | |||
| Cost of Revenue | 26.31% | 30.83% | |||
| Gross Profit | -16.60% | -25.27% | |||
| SG&A Expenses | 58.22% | -30.54% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 32.38% | 16.16% | |||
| Operating Income | -25.15% | -11.13% | |||
| Income Before Tax | -22.29% | -25.56% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -22.29% | -25.56% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -22.29% | -25.56% | |||
| EBIT | -25.15% | -11.13% | |||
| EBITDA | -24.89% | -9.78% | |||
| EPS Basic | 97.97% | -13.41% | |||
| Normalized Basic EPS | 97.97% | -13.41% | |||
| EPS Diluted | 97.97% | -13.41% | |||
| Normalized Diluted EPS | 97.97% | -13.41% | |||
| Average Basic Shares Outstanding | 5,935.00% | 10.72% | |||
| Average Diluted Shares Outstanding | 5,935.00% | 10.72% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||